The clinical and pathological features of patients with gastric cancer in Turkey: A Turkish Oncology Group Study

Turkish Journal of Cancer

Volumn 36, Issue 3, 2006, Pages 108-115

  Yalçin, Bülent ^a   Zengin, Nurullah ^b   Aydin, Fazil ^c   Ilhan, Mahmut ^d   Işikdoǧan, Abdurrahman ^e   Demir, Gökhan ^f   Aykan, Faruk ^g   Çelik, Ismail ^h   Dane, Faysal ⁱ   Üstüner, Zeki ^j   Börüban, M Cem ^k   Bozcuk, Hakan ^l   Coşkun, H Şenol ^m   Karaoǧlu, Aziz ⁿ   Altinbaş, Mustafa ^o   Yamaç, Deniz ^p   Tek, Ibrahim ^a   Budakoǧlu, Burçin ^b   Utkan, Güngör ^a   Özdemir, Feyyaz ^c   Aksoy, Sercan ^h   Özdemir, Nuriye ^b   Akbulut, Hakan ^a   Büyükçelik, Abdullah ^a   Içli, Fikri ^a   more..

^a ANKARA UNIVERSITY   (Turkey)

^b ANKARA TRAINING AND RESEARCH HOSPITAL   (Turkey)

^c KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^d YUZUNCU YIL UNIVERSITY   (Turkey)

^e DICLE UNIVERSITY   (Turkey)

^f ISTANBUL UNIVERSITY   (Turkey)

^g ISTANBUL UNIVERSITY   (Turkey)

^h HACETTEPE UNIVERSITY   (Turkey)

ⁱ MARMARA UNIVERSITY   (Turkey)

^j OSMANGAZI UNIVERSITY MEDICAL FACULTY   (Turkey)

^k SELCUK UNIVERSITY   (Turkey)

^l AKDENIZ UNIVERSITY   (Turkey)

^m SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

ⁿ FIRAT UNIVERSITY   (Turkey)

^o ERCIYES UNIVERSITY   (Turkey)

^p GAZI UNIVERSITY   (Turkey)

more..

Author keywords

Gastric cancer; Helicobacter pylori; Resectability

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURGERY; FEMALE; GASTRECTOMY; GASTRITIS; GEOGRAPHIC DISTRIBUTION; GEOGRAPHIC PATHOLOGY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INTESTINE METAPLASIA; MAJOR CLINICAL STUDY; MALE; QUESTIONNAIRE; SEX DIFFERENCE; SOCIAL STATUS; STOMACH CANCER; TURKEY (REPUBLIC);

EID: 34249658945     PISSN: 10193103     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Pisani P, Parkin DM, Bray F, et al. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29.
2. Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1997. CA Cancer J Clin 1997;47:5-27.
3. Curtis RE, Kennedy BJ, Myers MH, et al. Evaluation of AJC stomach cancer staging using the SEER population. Semin Oncol 1985;12:21-3.
4. Bonenkamp JJ, Hermans J, Sasako M. Extended lymph node dissection for gastric cancer. N Engl J Med. 1999;340:908-14.
5. Kodama Y, Sugimachi K, Soejima K, et al. Evaluation of extensive lymph node dissection for carcinoma of the stomach. World J Surg 1981;5:241-8.
6. Fukao A, Tsubono Y, Tsuji I, et al. The evaluation of screening for gastric cancer in Miyagi Prefecture, Japan: a population-based case-control study. Int J Cancer 1995;60:45-8.
7. Icli F, Celik I, Aykan F, et al. A randomized phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Cancer 1998;83:2475-80.
8. Yalcin B, Akbulut H, Buyukcelik A, et al. The effects of chronomodulated therapy with 5-fluorouracil (5-FU) and folinic acid (FA) on the toxicity and quality of life in patients with advanced gastric cancer. Biol Rhythm Res 2004;35:259-68.
9. Ajani JA, Van Custem E, Moiseyenko FC, et al. Docetaxel (D), cisplatin, 5-fluorouracil compared to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naive patients with metastatic or locally recurrent, unresectable gastric carcinoma: Interim results of a randomized phase III trial (V 325). Proc Am Soc Clin Oncol 2003;22:999 (abstr).
10. Firat D, Celik I. Cancer Statistics in Turkey and in the World 1993-1995 Turkish Association for the Cancer Research and Control. Ankara, 1998.
11. Cancer Statistics in Turkey (1999). http://www.saglik.gov.tr/sb/default. asp?sayfa=ozelistatistik&id=115&kelime=&page=
12. Karaoguz H, Icli F. Cancer problem in Turkiye. J Ankara Medical School 1993;15:547-58.
13. Percy C, Van Holten V, Muir C. International classification of diseases for oncology. 2nd ed. Geneva (Switzerland): World Health Organization; 1990.
14. Peek RM, Blaser MJ. Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2002;2:28-37.
15. Cinar K, Soykan I, Ozden A. The effect of Helicobacter pylori eradication in patients with functional dyspepsia: Assessment of different diagnostic tests. Turk J Gastroenterol 2004;15:159-63.
16. Kurtz RC, Sherlock P. The diagnosis of gastric cancer. Semin Oncol 1985;12:11-8.
17. Fenoglio-Preiser CM, Noffsinger AE, Belli J, et al. Pathologic and phenotypic features of gastric cancer. Semin Oncol 1996;23:292-306.
18. Talley NJ, Zinsmeister AR, Weaver A, et al. Gastric adenocarcinoma and Helicobacter pylori infection. J Natl Cancer Inst 1991;83:1734-9.
19. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of twelve case-control studies nested within prospective cohorts. Gut 2001;49:347-53.
20. Blot WJ, Devesa SS, Kneller RW, et al. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 1991;265:1287-9.
21. Hansson LE, Sparen P, Nyren O. Increasing incidence of both major histological types of esophageal carcinomas among men in Sweden. Int J Cancer 1993;54:402-7.